CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study

Igor Tsaur; Anika Noack; Jasmina Makarevic; Elsie Oppermann; Ana Maria Waaga-Gasser; Martin Gasser; Hendrik Borgmann; Tanja Huesch; Kilian M. Gust; Michael Reiter; David Schilling; Georg Bartsch; Axel Haferkamp; Roman A. Blaheta

doi:10.4143/crt.2014.015

Articles

Page Path: HOME > Cancer Res Treat > Volume 47(2); 2015 > Article

Original Article CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study: Igor Tsaur, MD¹, Anika Noack¹, Jasmina Makarevic¹, Elsie Oppermann², Ana Maria Waaga-Gasser, PhD³, Martin Gasser, MD³, Hendrik Borgmann, MD¹, Tanja Huesch, MD¹, Kilian M. Gust, MD¹, Michael Reiter, MD¹, David Schilling, MD¹, Georg Bartsch, MD¹, Axel Haferkamp, MD¹, Roman A. Blaheta, PhD¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2015;47(2):306-312.
DOI: https://doi.org/10.4143/crt.2014.015
Published online: October 13, 2014

¹Department of Urology and Pediatric Urology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany

²Department of Surgery, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany

³Department of Surgery I, University Hospital Wuerzburg, Julius-Maximilians-University, Wuerzburg, Germany

Correspondence: Igor Tsaur, MD Department of Urology and Pediatric Urology, Goethe University, Building 23, Room C337, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany
Tel: 49-69-6301-7671 Fax: 49-69-6301-81468 E-mail: igor.tsaur@kgu.de

• Received: January 12, 2014 • Accepted: March 25, 2014

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

17,468 Views
119 Download
50 Web of Science
41 Crossref
51 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Prostate specific antigen is not reliable in diagnosing prostate cancer (PCa), making the identification of novel, precise diagnostic biomarkers important. Since chemokines are associated with more aggressive disease and poor prognosis in diverse malignancies, we aimed to investigate the diagnostic relevance of chemokines in PCa.
Materials and Methods
Preoperative and early postoperative serum samples were obtained from 39 consecutive PCa patients undergoing radical prostatectomy. Serum from 15 healthy volunteers served as controls. Concentrations of CXCL12, CXCL13, CX3CL1, CCL2, CCL5, and CCL20 were measured in serum by Luminex. The expression activity of CXCR3, CXCR4, CXCR5, CXCR7, CXCL12, CXCL13, CX3CR1, CXCL1, CCR2, CCR5, CCR6, CCR7, CCL2, and CCL5 mRNA was assessed in tumor and adjacent normal tissue of prostatectomy specimens by quantitative real-time polymerase chain reaction. The associations of these chemokines with clinical and histological parameters were tested.
Results
The gene expression activity of CCL2 and CCR6 was significantly higher in tumor tissue compared to adjacent normal tissue. CCL2 was also significantly higher in the blood samples of PCa patients, compared to controls. CCL5, CCL20, and CX3CL1 were lower in patient serum, compared to controls. CCR2 tissue mRNA was negatively correlated with the Gleason score and grading.
Conclusion
Chemokines are significantly modified during tumorigenesis of PCa, and CCL2 is a promising diagnostic biomarker.
Key words: Prostatic neoplasms, Diagnosis, Biological markers, Chemokines, Chemokine CCL2

Introduction

Since serum prostate specific antigen (PSA) was introduced as an early detection marker of prostate cancer (PCa) in the 1980s, several trials involving novel and more precise biomarkers have failed to provide new markers with definitive clinical relevance and applicability. Considering the low sensitivity of PSA and the importance of distinguishing latent from clinically significant PCa to optimize treatment, the need for specific diagnostic markers is apparent. Recent investigations have pointed to caveolin-1 [1], exosomes [2], and PCA-3 [3] as diagnostic markers. However, their clinical applicability is still to be determined.

This pilot study was designed to investigate the potential of chemokines as biomarkers for PCa. Chemokines are low molecular weight secretory proteins divided into four groups (CXC, CC, C, and the CX3C family [4]) according to the arrangement of conserved cysteine (C) residues of the mature proteins, which interact as ligands (CL) with their corresponding receptors (CR). Due to their proinflammatory properties, chemokines regulate chemotaxis and metabolic activity of leukocytes circulating in the body and therefore significantly affect normal development, angiogenesis and atherosclerosis [4,5]. They are involved in many aspects of oncogenesis, including regulation of cancer cell growth, dissemination and host-tumor response [6,7]. Hence, various tumor types differentially trigger a complex chemokine network determining the qualitative and quantitative degree of immunocellular infiltration [8]. Alterations of the chemokine expression level are significantly associated with more aggressive disease and poorer prognosis in diverse malignancies [9,10]. However, their role in the tumorigenesis of PCa is unknown. Preliminary work pointed out the potential of CXC chemokines as prognostic biomarkers for PCa [11]. To assess the diagnostic relevance of chemokines in PCa, the expression of a broad panel of chemokines in tumor tissue and their serum levels in patients with PCa was investigated and associations tested with clinical and pathological parameters.

Materials and Methods

1. Patients

The local medical ethics committee approved the study. Patients undergoing radical prostatectomy for biopsyproven PCa between January 2008 and October 2010 in the Department of Urology, Goethe University, Frankfurt, Germany, were included in the study after signing informed consent for utilization of biomaterials and further scientific assessment. The tumor stage and grade was determined according to the sixth edition of the TNM classification [12]. Tumors were graded with the Gleason score [13] as well. Clinical parameters, including the patient’s age and preoperative and postoperative PSA values, were documented.

2. Blood samples

Ten milliliters of peripheral blood was drawn from patients the day before surgery and 5 to 7 days after surgery. As controls, 10 mL blood was drawn from 15 healthy, male, age-matched volunteers. Blood samples were allowed to coagulate and then centrifuged at 3,000 rpm at 4°C for 10 minutes. The serum supernatant was stored at –80°C.

3. Luminex analysis

The human cytokine multiplex bead assay kit (Millipore, Darmstadt, Germany) was used to determine CXCL12, CXCL13, CX3CL1, CCL2, CCL5, and CCL20 in serum, according to the manufacturer’s instructions. The filter plate was pre-wetted with 200 μL of washing solution. Anti-chemokine antibody coated beads (25 μL) were pipetted into each well. The plates were washed using a vacuum manifold. Samples (serum) or standards (25 μL) were then added to the wells and incubated with the beads for 2 hours. After washing, biotin conjugated detector antibody was added and incubated for 1 hour, followed by a 30-minute incubation with R-phycoerythrin conjugated streptavidin. All incubation steps were performed at room temperature in the dark. Analysis was carried out with a Luminex 100 (Gurce, Nivelles, Belgium) and expressed as pg/mL.

4. Tissue samples

Immediately after resection, tissue was transferred to the Department of Pathology and reviewed by a pathologist. Tumor tissue, as well as adjacent normal tissue, was fresh-frozen in liquid nitrogen.

5. RNA Isolation

Total RNA from solid tumor tissue of patients with PCa and adjacent normal tissue was extracted using RNeasy kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. Solid tissues were sliced into small pieces and transferred to a Precellys tube pre-filled with 1.4-mm ceramic beads (Bertin Technologies, Saint-Quentin-en-Yvelines Cedex, France) containing lysis buffer. Cells were lysed under rapid agitation at 6,500 rpm for 1 minute in three cycles using a Precellys 24 homogenizer (Bertin Technologies). cDNA was synthesized from 1 μg of total RNA with oligo(dT) primer using an AffinityScript QPCR cDNA synthesis kit (Stratagene, Santa Clara, CA), according to the manufacturer’s instructions. The amount and quality of RNA were analyzed using Nanovue (GE Healthcare, Piscataway, NJ) and bioanalyzer (Agilent Technologies, Palo Alto, CA), respectively.

6. Real-time polymerase chain reaction (PCR)

Real-time quantitative PCR (qRT-PCR) was performed using RT² SYBR-Green/RoxqPCR master mix and gene specific primers for CL and CR (both from Sabioscience, Madison, WI) (Table 1), according to the manufacturer’s protocol. Gene amplification was performed using MX3005P (Stratagene). One hundred nanograms of cDNA was used in the qPCR reaction in duplicate. The dissociation curve was checked at the end of each PCR reaction. Glyceraldehyde 3-phosphate dehydrogenase and β-actin were used as housekeeping gene and for normalization. Gene expression (fold change) was calculated using the ΔΔC_t method, after normalizing the tumor sample with a corresponding normal sample.

7. Statistics

All experiments were performed three to six times. Statistical significance of differences between parameters within the same group was tested by the Wilcoxon matched pairs test and in different groups by the Wilcoxon Mann-Whitney test. Subgroup analyses employed the Kruskal-Wallis test with the Iman-Conover method (Bonferroni-Holm correction). Correlation between two parameters was evaluated by the analysis of Spearman’s coefficient. Linear regression was assessed by Pearson’s linear regression test. The statistical program applied was BiAS for Windows (ver. 9.11, Dr. rer. nat. Hanns Ackermann, Epsilon Publishers, Frankfurt, Germany). Null hypotheses of no difference were rejected if p-values were less than 0.05. Continuous data are presented as mean±standard deviation.

Results

The study population consisted of 39 patients (Table 2) with a mean age at tumor diagnosis of 68.9±5.6 years. None of the patients had evident clinical signs of infection or acute or chronic inflammation at the time of surgery. Histologically, all tumors were conventional acinar adenocarcinomas. In four patients the final histopathological analysis revealed positive margins (R1). Limited lymph node metastasis was detected in two other patients (N1). Perineural infiltration (Pn1) was found in 10 patients. All patients with microscopic residual disease (R1) and five other patients (2× pT3a, 2× pT3b and 1× pT2c with biochemical relapse after surgery) received radiation therapy. The mean follow-up time was 18.1±15.1 months. At the study endpoint, all patients were alive without signs of biochemical or clinical recurrence.

Using qRT-PCR, significantly higher expression of CCL2 and CCR6 in tumor tissue was observed, compared to normal adjacent tissue (Fig. 1). The expression of CXCR4, CX3CR1, CCR2, CCR5, CCR7, CCL5, and CCL20 was higher and that of CXCR3, CXCR5, CXCR7, CXCL12, CXCL13, and CX3CL1 lower in the tumor tissue without reaching significance.

The association of gene expression of the chemokines in the tumor tissue was tested with clinical and oncologic parameters (Fig. 2). CCR2 revealed a significant negative linear correlation with the Gleason score and grading. No association was found between the other investigated chemokines and T stage, Gleason score, grade, R1- and Pn1-status, preoperative and postoperative PSA or biochemical relapse.

The chemokine concentration in serum was determined with Luminex (Fig. 3). CCL2 was significantly over-expressed both preoperatively and postoperatively in PCa patients, compared to controls. Significantly diminished concentrations of CCL5 in preoperative and postoperative samples were detected, compared to controls. The concentration of CCL20 increased significantly in the control group, compared to both preoperative and postoperative serum concentration in PCa patients. The serum concentration of CX3CL1 also increased significantly in the controls compared to that in patient serum, both preoperatively and postoperatively. The level of CXCL12 and CXCL13 did not significantly differ among any of the groups.

The association of chemokine serum concentrations with T stage, Gleason score, grade, R1- and Pn1-status, preoperative PSA as well as biochemical relapse were then tested. CCL2 was significantly negatively correlated with the preoperative PSA value (Spearman’s correlation coefficient rho, –0.48; p=0.035). No associations among these parameters and the other chemokines were apparent.

Discussion

Chemokines are small secreted chemotactic cytokines that coordinate immunological machinery by promoting leukocyte migration and cross-communication among different cell types of the immune system [14]. Due to similarities between leukocyte trafficking and cancer cell dissemination, the role of chemokines in tumorigenesis is drawing increasing attention [15]. Recent studies regarding different tumor entities point to significant involvement of chemokines in facilitating tumor promotion and dissemination [16]. The present data explore the potential of chemokines as biomarkers in patients with PCa.

Based on the evaluation of 15 members of the chemokine family, evidence is provided here that the gene activity of particular molecules is altered in PCa, compared to normal tissue. CCL2 and CCR6 mRNA were overexpressed in the tumor specimens, compared to adjacent normal tissue. CCL2, but not CCR6, was also significantly augmented in serum from tumor patients compared to healthy controls, indicating a critical role of CCL2 in neoplastic progression. A meta-analysis of gene-expression data has identified CCL2 as a primary driver in PCa development [17]. Immunohistochemistry and immunofluorescence analysis of the chemokine expression profile reveal CCL2 to be predominantly expressed at the tumor site, more than for other chemokines [18]. Tissue microarray analysis shows that levels of CCL2 expression in PCa tissue are greater than in non-neoplastic epithelia [19]. Therefore, CCL2 could serve as a specific diagnostic marker, closely associated with PCa, even though CCL2 did not reach control values postoperatively. A possible explanation is that immunologic processes are still active five to seven days after surgical intervention. Studies incorporating blood sampling at later post-surgical dates should, therefore, more clearly define the specific diagnostic value of CCL2. One problem in employing CCL2 to diagnose PCa is the lack of association with tumor stage and grade, meaning that CCL2 may not allow evaluation of tumor dissemination. Shirotake et al. [20] found differences in CCL2 levels only between very early localized, and advanced castration resistant PCa. In contrast, the report from Lu et al. [19] pointed to a significant relationship between CCL2 level and Gleason score. Different analytic techniques (microarray) or a selected patient cohort (Asian) may account for this discrepancy. Obviously, further patient studies are necessary to clarify the diagnostic value of CCL2 for PCa.

CCL5, CCL20, and CX3CL1 were all reduced in patient sera, whereas no differences were seen in the gene analyses. Therefore, PCa progression seems accompanied by alterations in CCL5, CCL20, and CX3CL1 protein release but not in transcriptional modification. Data concerning this issue are sparse. In a recent report, CCL5 serum level was not altered in PCa patients, compared to controls. However, this study was limited to PCa with serum PSA values of < 10 ng/mL [21], which cannot be applied to our cohort with 41% of patients with a preoperative PSA > 10 ng/mL. Immunohistochemistry of 80 PCa cases revealed absent or weak CCL20 expression in 61%, whereas strong staining was evident in only 10% of patients [22]. This may corroborate our CCL20 data, although serum probes were not analyzed in this study [22]. CX3CL1 is down-regulated in high-risk PCa patients who develop biochemical recurrence following prostatectomy [23]. The authors of this case-control study recommend CX3CL1 as a potential indicator of future recurrence.

CXCL12 was not different between PCa patients and controls. CXCL12 is suggested to facilitate tumor cell recruitment to the bone marrow and a high CXCL12 expression is associated with lymph node metastatic prostate carcinoma compared with non–lymph-node metastatic cancer in an immunohistochemical analysis [24]. Semiquantitative PCR evaluation points to an enhanced CXCL12 mRNA expression level in prostate tumor, compared to adjacent 'normal' tissue [11]. Serum CXCL12 levels are significantly higher for men who were biopsy positive compared to those who were biopsy negative for PCa [25].

In contrast, Agarwal et al. [21], who performed multiplex enzyme-linked immunosorbent assay assays on 272 men, found no association between CXCL12 and PCa status [21]. These results agree with the present investigation. A final assessment of the role of CXCL12 in PCa is difficult since different techniques have been applied in relevant studies. More research is required to better interpret the clinical significance of CXCL12.

Conclusion

In conclusion, particular chemokines have been shown to be related to PCa. The CCL2 changes dominate other chemokine changes, since PCa related CCL2 alterations were found at both gene and protein level. However, CCR6, CCL5, CCL20, and CX3CL1 might be further candidates pointing to neoplastic transformation. Further large-volume biomarker studies are required to expand and validate the preliminary findings of this pilot study.

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

We would like to thank Karen Nelson for critically reading the manuscript and Dr. Hanns Ackermann for statistical supervision. Grant from the “Heinrich und Erna Schaufler-Stiftung” (received 2012, principal investigator: Igor Tsaur).

Fig. 1.

Analysis of chemokine gene activity obtained with real-time quantitative polymerase chain reaction in tumor tissue compared to normal adjacent tissue in patients with prostate cancer. Vertical line, Tukey confidence interval for Hodges-Lehmann estimator; ●, lower and upper limit of the Tukey confidence interval; ▲, Hodges-Lehmann estimator of the median fold difference.

Fig. 2.

Results from Pearson’s regression test for chemokine expression in prostate cancer samples and tumor grade or Gleason score. Presented as regression line (thick) and confidence borders (thin lines) with confidence p=0.95. p, p-value of the regression test; B, regression coefficient; r, Pearson’s correlation coefficient. Chemokine expression as fold difference obtained with real-time quantitative polymerase chain reaction.

Fig. 3.

Chemokine concentration obtained with Luminex. Chemokines with significant differences between at least two samples are presented. Box-plot: Con, control serum; Pre, preoperative serum; Post, postoperative serum. Box: lower line, quartile Q1 (25%-quantile); middle line, median; upper line, Q3 (75%-quantile); aerials, extreme values; horizontal bracket, respective p-value of the concentration difference in Wilcoxon-matched-pairs or Wilcoxon-Mann-Whitney test.

Table 1.

Gene specific primers used for qRT-PCR with catalogue numbers

Primer	Catalog No.
CXCR3	PPH01041A-200
CXCR4	PPH00621A-200
CXCR5	PPH01034A-200
CXCR7	PPH01182E-200
CXCL12	PPH00528B-200
CXCL13	PPH01168E-200
CX3CR1	PPH00620A-200
CX3CL1	PPH00689B-200
CCR2	PPH00612E-200
CCR5	PPH00615E-200
CCR6	PPH00616E-200
CCR7	PPH00617A-200
CCL2	PPH00192E-200
CCL5	PPH00703A-200
CCL20	PPH00564B-200
GAPDH	PPH00150E-200

qRT-PCR, real-time quantitative polymerase chain reaction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

Table 2.

Clinical and histopathological characteristics of the study cohort

Parameter	No. (%)
Age (yr)	68.9±5.6
PSA (ng/mL)	10.3±6.5
≤ 10	23 (59.0)
10-20	13 (33.3)
> 20	3 (7.7)
T stage
pT2a	4 (10.3)
pT2b	1 (2.6)
pT2c	21 (53.8)
pT3a	7 (17.9)
pT3b	6 (15.4)
pT4	0
Grade
1	0
2	24 (61.5)
3	15 (38.5)
Gleason score
5	5 (12.8)
6	10 (25.6)
7	13 (33.3)
8	7 (18.0)
9	4 (10.3)

Age and preoperative prostate specific antigen (PSA) expressed as mean±standard deviation.

REFERENCES

1. Gumulec J, Sochor J, Hlavna M, Sztalmachova M, Krizkova S, Babula P, et al. Caveolin-1 as a potential high-risk prostate cancer biomarker. Oncol Rep. 2012;27:831–41. PubMed
2. Principe S, Jones EE, Kim Y, Sinha A, Nyalwidhe JO, Brooks J, et al. In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine. Proteomics. 2013;13:1667–71. Article PubMed PMC
3. Shen M, Chen W, Yu K, Chen Z, Zhou W, Lin X, et al. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population. Exp Mol Pathol. 2011;90:97–100. Article PubMed
4. Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A. Chemokines and chemokine receptors: an overview. Front Biosci (Landmark Ed). 2009;14:540–51. Article PubMed
5. Lin TH, Liu HH, Tsai TH, Chen CC, Hsieh TF, Lee SS, et al. CCL2 increases alphavbeta3 integrin expression and subsequently promotes prostate cancer migration. Biochim Biophys Acta. 2013;1830:4917–27. Article PubMed
6. Craig MJ, Loberg RD. CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Rev. 2006;25:611–9. Article PubMed
7. Homey B, Muller A, Zlotnik A. Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol. 2002;2:175–84. Article PubMed
8. Kulbe H, Levinson NR, Balkwill F, Wilson JL. The chemokine network in cancer--much more than directing cell movement. Int J Dev Biol. 2004;48:489–96. Article PubMed
9. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol. 2004;14:181–5. Article PubMed
10. Strieter RM, Belperio JA, Phillips RJ, Keane MP. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol. 2004;14:195–200. Article PubMed
11. Wedel SA, Raditchev IN, Jones J, Juengel E, Engl T, Jonas D, et al. CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancer. Mol Med Rep. 2008;1:257.PubMed
12. Wittekind C, Meyer HJ, Bootz F. UICC: TNM Klassifikation maligner Tumoren. 6. Auflage. Berlin: Springer; 2002.
13. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29:1228–42. Article PubMed
14. Waugh DJ, Wilson C, Seaton A, Maxwell PJ. Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci. 2008;13:4595–604. Article PubMed
15. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 2007;98:1652–8. Article PubMed PMC
16. Tsaur I, Noack A, Waaga-Gasser AM, Makarevic J, Schmitt L, Kurosch M, et al. Chemokines involved in tumor promotion and dissemination in patients with renal cell cancer. Cancer Biomark. 2011;10:195–204. Article PubMed
17. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, et al. Prioritizing genes associated with prostate cancer development. BMC Cancer. 2010;10:599.Article PubMed PMC
18. Izhak L, Wildbaum G, Weinberg U, Shaked Y, Alami J, Dumont D, et al. Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner. J Immunol. 2010;184:1092–101. Article PubMed
19. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 2006;66:1311–8. Article PubMed
20. Shirotake S, Miyajima A, Kosaka T, Tanaka N, Kikuchi E, Mikami S, et al. Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. Am J Pathol. 2012;180:1008–16. Article PubMed
21. Agarwal M, He C, Siddiqui J, Wei JT, Macoska JA. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate. 2013;73:573–81. Article PubMed PMC
22. Ghadjar P, Loddenkemper C, Coupland SE, Stroux A, Noutsias M, Thiel E, et al. Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. J Cancer Res Clin Oncol. 2008;134:1181–9. Article PubMed PMC
23. Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, et al. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res. 2008;14:7790–7. Article PubMed PMC
24. Wang Q, Diao X, Sun J, Chen Z. Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy. Urol Oncol. 2013;31:312–7. Article PubMed
25. Macoska JA, Begley LA, Dunn RL, Siddiqui J, Wei JT, Sarma AV. Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA. Prostate. 2008;68:442–52. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Harnessing immunotherapeutic molecules and diagnostic biomarkers as human-derived adjuvants for MERS-CoV vaccine development
Abdullah R. Alrasheed, Maaweya Awadalla, Hadeel Alnajran, Mohammed H. Alammash, Adil M. Almaqati, Ishtiaq Qadri, Bandar Alosaimi
Frontiers in Immunology.2025;[Epub] CrossRef
Immune System Alterations in the Development of Three Urological Cancers: Insights from Large-Sample Mendelian Randomization
Zhijian Chen, Ye Xie, Xiong Chen, Guibin Hong, Runnan Shen, Haishan Lin, Fan Jiang, Yun Wang, Mengyi Zhu, Yixuan Liu, Haoxuan Wang, Hongkun Yang, Tianxin Lin, Shaoxu Wu
Biomedicines.2025; 13(6): 1480. CrossRef
Single-cell RNA sequencing reveals intratumoral heterogeneity and potential mechanisms of malignant progression in prostate cancer with perineural invasion
Bao Zhang, Shenghan Wang, Zhichao Fu, Qiang Gao, Lin Yang, Zhentao Lei, Yuqiang Shi, Kai Le, Jie Xiong, Siyao Liu, Jiali Zhang, Junyan Su, Jing Chen, Mengyuan Liu, Beifang Niu
Frontiers in Genetics.2023;[Epub] CrossRef
Osteoid cell-derived chemokines drive bone-metastatic prostate cancer
Catherine S. Johnson, Leah M. Cook
Frontiers in Oncology.2023;[Epub] CrossRef
Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?
Clara Martori, Lidia Sanchez-Moral, Tony Paul, Juan Carlos Pardo, Albert Font, Vicenç Ruiz de Porras, Maria-Rosa Sarrias
Cancers.2022; 14(2): 440. CrossRef
Plasma Chemokine C-C Motif Ligand 2 as a Potential Biomarker for Prostate Cancer
Martin Lund, Torben B Pedersen, Søren Feddersen, Louise D Østergaard, Charlotte A Poulsen, Christian Enggaard, Mads H Poulsen, Lars Lund
Research and Reports in Urology.2022; Volume 14: 33. CrossRef
Potential PET tracers for imaging of tumor-associated macrophages
Bruna Fernandes, Paula Kopschina Feltes, Carolina Luft, Luiza Reali Nazario, Cristina Maria Moriguchi Jeckel, Ines F. Antunes, Philip H. Elsinga, Erik F. J. de Vries
EJNMMI Radiopharmacy and Chemistry.2022;[Epub] CrossRef
Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study
Hiroaki Iwamoto, Kouji Izumi, Ryunosuke Nakagawa, Ren Toriumi, Shuhei Aoyama, Takafumi Shimada, Hiroshi Kano, Tomoyuki Makino, Suguru Kadomoto, Hiroshi Yaegashi, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, Yoshifumi Kadono, Atsushi Mizokami
Japanese Journal of Clinical Oncology.2022;[Epub] CrossRef
Potential mechanisms ofPyrrosiae Foliumin treating prostate cancer based on network pharmacology and molecular docking
Wen-Hua Guo, Kun Zhang, Lu-Hong Yang
Drug Development and Industrial Pharmacy.2022; 48(5): 189. CrossRef
White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions
Achinto Saha, Jill Hamilton-Reeves, John DiGiovanni
Cancer and Metastasis Reviews.2022; 41(3): 649. CrossRef
Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer
Hiroaki Iwamoto, Kouji Izumi, Ryunosuke Nakagawa, Ren Toriumi, Shuhei Aoyama, Taiki Kamijima, Takafumi Shimada, Hiroshi Kano, Tomoyuki Makino, Renato Naito, Suguru Kadomoto, Hiroshi Yaegashi, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, Yoshifu
Biomedicines.2022; 10(10): 2369. CrossRef
Does C-C Motif Chemokine Ligand 2 (CCL2) Link Obesity to a Pro-Inflammatory State?
Sebastian Dommel, Matthias Blüher
International Journal of Molecular Sciences.2021; 22(3): 1500. CrossRef
Characterization of the perioperative changes of exosomal immune-related cytokines induced by prostatectomy in early-stage prostate cancer patients
Mónica Macías, Ángel García-Cortés, Marcos Torres, Javier Ancizu-Marckert, Juan Ignacio Pascual, Fernando Díez-Caballero, José Enrique Robles, David Rosell, Bernardino Miñana, Beatriz Mateos, Daniel Ajona, Rodrigo Sánchez-Bayona, Oihane Bedialauneta, Susa
Cytokine.2021; 141: 155471. CrossRef
Research Trends and Regulation of CCL5 in Prostate Cancer
Renlun Huang, Lang Guo, Menghan Gao, Jing Li, Songtao Xiang
OncoTargets and Therapy.2021; Volume 14: 1417. CrossRef
Expression of CCL2/CCR2 signaling proteins in breast carcinoma cells is associated with invasive progression
Wei Bin Fang, Diana Sofia Acevedo, Curtis Smart, Brandon Zinda, Nadia Alissa, Kyle Warren, Garth Fraga, Li-Ching Huang, Yu Shyr, Wei Li, Lu Xie, Vincent Staggs, Yan Hong, Fariba Behbod, Nikki Cheng
Scientific Reports.2021;[Epub] CrossRef
CCL2 (C-C Motif Chemokine Ligand 2) Biomarker Responses in Central Versus Peripheral Compartments After Focal Cerebral Ischemia
Jingfei Shi, Wenlu Li, Fang Zhang, Ji Hyun Park, Hong An, Shuzhen Guo, Yunxia Duan, Di Wu, Kazuhide Hayakawa, Eng H. Lo, Xunming Ji
Stroke.2021; 52(11): 3670. CrossRef
On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances
Yiwu Yan, Su Yeon Yeon, Chen Qian, Sungyong You, Wei Yang
International Journal of Molecular Sciences.2021; 22(24): 13537. CrossRef
Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting
Tetiana Hourani, James A. Holden, Wenyi Li, Jason C. Lenzo, Sara Hadjigol, Neil M. O’Brien-Simpson
Frontiers in Oncology.2021;[Epub] CrossRef
Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?
Nathan Karin
Cancers.2021; 13(24): 6317. CrossRef
Genetically predicted levels of circulating cytokines and prostate cancer risk: A Mendelian randomization study
Xiaohui Sun, Ding Ye, Lingbin Du, Yu Qian, Xia Jiang, Yingying Mao
International Journal of Cancer.2020; 147(9): 2469. CrossRef
SFMBT2-Mediated Infiltration of Preadipocytes and TAMs in Prostate Cancer
Jungsug Gwak, Hayan Jeong, Kwanghyun Lee, Jee Yoon Shin, Taejun Sim, Jungtae Na, Jongchan Kim, Bong-Gun Ju
Cancers.2020; 12(9): 2718. CrossRef
The Development and Homing of Myeloid-Derived Suppressor Cells: From a Two-Stage Model to a Multistep Narrative
Nathan Karin
Frontiers in Immunology.2020;[Epub] CrossRef
Can Blood-Circulating Factors Unveil and Delay Your Biological Aging?
Natalia Rybtsova, Tatiana Berezina, Alexander Kagansky, Stanislav Rybtsov
Biomedicines.2020; 8(12): 615. CrossRef
Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine
Orazio Schillaci, Manuel Scimeca, Donata Trivigno, Agostino Chiaravalloti, Simone Facchetti, Lucia Anemona, Rita Bonfiglio, Giuseppe Santeusanio, Virginia Tancredi, Elena Bonanno, Nicoletta Urbano, Alessandro Mauriello
Nuclear Medicine and Biology.2019; 68-69: 66. CrossRef
Role of ALDH1A1 and HTRA2 expression to CCL2/CCR2 mediated breast cancer cell growth and invasion
Qingting Hu, Megan Myers, Wei Fang, Min Yao, Gage Brummer, Justin Hawj, Curtis Smart, Cory Berkland, Nikki Cheng
Biology Open.2019;[Epub] CrossRef
Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients
Takumi Kishimoto, Nobukazu Fujimoto, Takeshi Ebara, Toyonori Omori, Tetsuya Oguri, Akio Niimi, Takako Yokoyama, Munehiro Kato, Ikuji Usami, Masayuki Nishio, Kosho Yoshikawa, Takeshi Tokuyama, Mouka Tamura, Yoshifumi Yokoyama, Ken Tsuboi, Yoichi Matsuo, Ji
BMC Cancer.2019;[Epub] CrossRef
RETRACTED: Elevated Expression Levels of PC3-Secreted Microprotein (PSMP) in Prostate Cancer Associated With Increased Xenograft Growth and Modification of Immune-Related Microenvironment
Xiaolei Pei, Danfeng Zheng, Shaoping She, Zhiwei Fang, Shiying Zhang, Hao Hu, Kexin Xu, Ying Wang
Frontiers in Oncology.2019;[Epub] CrossRef
More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis
Martha Gschwandtner, Rupert Derler, Kim S. Midwood
Frontiers in Immunology.2019;[Epub] CrossRef
Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features
Catarina Ferreira, João Lobo, Luís Antunes, Paula Lopes, Carmen Jerónimo, Rui Henrique
Virchows Archiv.2018; 473(4): 443. CrossRef
Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target Genes
Jaroslaw Szczyrba, Volker Jung, Michaela Beitzinger, Elke Nolte, Sven Wach, Martin Hart, Sandra Sapich, Marc Wiesehöfer, Helge Taubert, Gunther Wennemuth, Norbert Eichner, Thomas Stempfl, Bernd Wullich, Gunter Meister, Friedrich A. Grässer
Prostate Cancer.2017; 2017: 1. CrossRef
Insulin secretagogue use and circulating inflammatory C–C chemokine levels in breast cancer patients
Zachary A.P. Wintrob, Jeffrey P. Hammel, George K. Nimako, Zahra S. Fayazi, Dan P. Gaile, Alan Forrest, Alice C. Ceacareanu
Data in Brief.2017; 11: 391. CrossRef
Data report on inflammatory C–C chemokines among insulin-using women with diabetes mellitus and breast cancer
Zachary A.P. Wintrob, Jeffrey P. Hammel, George K. Nimako, Zahra S. Fayazi, Dan P. Gaile, Erin E. Davis, Alan Forrest, Alice C. Ceacareanu
Data in Brief.2017; 11: 446. CrossRef
Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis
Matteo Santoni, Liang Cheng, Alessandro Conti, Cinzia Mariani, Antonio Lopez-Beltran, Rodolfo Montironi, Nicola Battelli
European Urology Supplements.2017; 16(12): 301. CrossRef
Association of mast cell infiltration with gastric cancer progression
Bei Zhong, Yu Li, Xiaodong Liu, Dongsheng Wang
Oncology Letters.2017;[Epub] CrossRef
Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer
Tomomi Fujii, Keiji Shimada, Yoshihiro Tatsumi, Nobumichi Tanaka, Kiyohide Fujimoto, Noboru Konishi
Molecular Carcinogenesis.2016; 55(9): 1378. CrossRef
Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review
Alessandro Sciarra, Alessandro Gentilucci, Stefano Salciccia, Federico Pierella, Flavio Del Bianco, Vincenzo Gentile, Ida Silvestri, Susanna Cattarino
Journal of Inflammation.2016;[Epub] CrossRef
Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model
Stefano Garetto, Claudia Sardi, Elisa Martini, Giuliana Roselli, Diego Morone, Roberta Angioni, Beatrice Claudia Cianciotti, Anna Elisa Trovato, Davide Giuseppe Franchina, Giovanni Francesco Castino, Debora Vignali, Marco Erreni, Federica Marchesi, Cristi
Oncotarget.2016; 7(28): 43010. CrossRef
Inflammation and prostate cancer: friends or foe?
Gianluigi Taverna, Elisa Pedretti, Giuseppe Di Caro, Elena Monica Borroni, Federica Marchesi, Fabio Grizzi
Inflammation Research.2015; 64(5): 275. CrossRef
CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro
Igor Tsaur, Jochen Rutz, Jasmina Makarević, Eva Juengel, Kilian M. Gust, Hendrik Borgmann, David Schilling, Karen Nelson, Axel Haferkamp, Georg Bartsch, Roman A. Blaheta
World Journal of Urology.2015; 33(7): 1051. CrossRef
sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients
Igor Tsaur, Kristina Thurn, Eva Juengel, Kilian M. Gust, Hendrik Borgmann, Rene Mager, Georg Bartsch, Elsie Oppermann, Hanns Ackermann, Karen Nelson, Axel Haferkamp, Roman A. Blaheta
Journal of Experimental & Clinical Cancer Research.2015;[Epub] CrossRef
The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer
Firas Abdollah, Deepansh Dalela, Michael C. Haffner, Zoran Culig, Jack Schalken
European Urology Focus.2015; 1(2): 99. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study

Cancer Res Treat. 2015;47(2):306-312. Published online October 13, 2014

DOI: https://doi.org/10.4143/crt.2014.015

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
NOTES
REFERENCES

CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study

Fig. 1. Analysis of chemokine gene activity obtained with real-time quantitative polymerase chain reaction in tumor tissue compared to normal adjacent tissue in patients with prostate cancer. Vertical line, Tukey confidence interval for Hodges-Lehmann estimator; ●, lower and upper limit of the Tukey confidence interval; ▲, Hodges-Lehmann estimator of the median fold difference.

Fig. 2. Results from Pearson’s regression test for chemokine expression in prostate cancer samples and tumor grade or Gleason score. Presented as regression line (thick) and confidence borders (thin lines) with confidence p=0.95. p, p-value of the regression test; B, regression coefficient; r, Pearson’s correlation coefficient. Chemokine expression as fold difference obtained with real-time quantitative polymerase chain reaction.

Fig. 3. Chemokine concentration obtained with Luminex. Chemokines with significant differences between at least two samples are presented. Box-plot: Con, control serum; Pre, preoperative serum; Post, postoperative serum. Box: lower line, quartile Q1 (25%-quantile); middle line, median; upper line, Q3 (75%-quantile); aerials, extreme values; horizontal bracket, respective p-value of the concentration difference in Wilcoxon-matched-pairs or Wilcoxon-Mann-Whitney test.

Fig. 1.

Fig. 2.

Fig. 3.

CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study

Primer	Catalog No.
CXCR3	PPH01041A-200
CXCR4	PPH00621A-200
CXCR5	PPH01034A-200
CXCR7	PPH01182E-200
CXCL12	PPH00528B-200
CXCL13	PPH01168E-200
CX3CR1	PPH00620A-200
CX3CL1	PPH00689B-200
CCR2	PPH00612E-200
CCR5	PPH00615E-200
CCR6	PPH00616E-200
CCR7	PPH00617A-200
CCL2	PPH00192E-200
CCL5	PPH00703A-200
CCL20	PPH00564B-200
GAPDH	PPH00150E-200

Parameter	No. (%)
Age (yr)	68.9±5.6
PSA (ng/mL)	10.3±6.5
≤ 10	23 (59.0)
10-20	13 (33.3)
> 20	3 (7.7)
T stage
pT2a	4 (10.3)
pT2b	1 (2.6)
pT2c	21 (53.8)
pT3a	7 (17.9)
pT3b	6 (15.4)
pT4	0
Grade
1	0
2	24 (61.5)
3	15 (38.5)
Gleason score
5	5 (12.8)
6	10 (25.6)
7	13 (33.3)
8	7 (18.0)
9	4 (10.3)

Table 1. Gene specific primers used for qRT-PCR with catalogue numbers

qRT-PCR, real-time quantitative polymerase chain reaction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

Table 2. Clinical and histopathological characteristics of the study cohort

Age and preoperative prostate specific antigen (PSA) expressed as mean±standard deviation.